Seamus Mulligan - 05 Aug 2026 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Reporting relationship: Director
Issuer ticker: JAZZ
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 17:42:20 UTC
Prior SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: By: /s/Paz Dizon, as attorney in fact For: Seamus Mulligan

Key filing fact

Seamus Mulligan filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 07 Aug 2026.

Key facts

This page summarizes Seamus Mulligan's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Aug 2026, 17:42.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001536639 Primary reporting owner

Mulligan Seamus

Relationship: Director
Address: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND
Signature: By: /s/Paz Dizon, as attorney in fact For: Seamus Mulligan
Signature date: 07 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAZZ transaction

Ordinary Shares

Award

Transaction value
Shares: +1,605
Change %: +0.14%
Price: $0.000000^*
Shares after: 1,184,633
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F1

JAZZ holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 101,621
Date: 05 Aug 2026
Ownership: By Nerano Pharma Lim
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.

Footnote F2

Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.